Tuesday, February 14, 2017 6:25:35 PM
Then pile on this latest news about the criminal investigation, which really sucks. Even if the company can escape any legal penalty for wrong-doing, if their clinical process is questionable, you can forget about FDA approval based on current results. This pushes the time-frame for KIT-302 even further out, which really chisels away at the value of warrants.
And credibility? This had been one of the company's strong points moving ahead- the line-up of seasoned industry and FDA-experienced pros who knew how to get an NDA over the line. That's all up in smoke now IMO. Reputation is everything: whether officials in the company acted criminally or not, the damage has been done.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM